Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M...

Vilcek Foundation Prizes for Creative Promise in Biomedical Science are being accepted now through June 9, 2025. These $50,000 prizes are given each year to three early- to mid-career immigrant...

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of FZ002 for C. difficile...

Currax Pharmaceuticals LLC a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion HCl), announced the publication of...

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to...

Kenox Pharmaceuticals Inc. and Lactiga US, Inc. are pleased to announce a strategic collaboration to advance the development of novel, groundbreaking, mucosal-targeted Secretory IgA (sIgA) therapies for...

UCB, a global biopharmaceutical company, announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with...

MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), announced additional funding from existing investors, Debiopharm Innovation Fund, Nina...

In a significant development for the clinical diagnostics landscape in Singapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their...

Shorla Oncology a U.S.-Ireland specialty pharmaceutical company, announced the launch of a dedicated sales force and market access teams and the commercial availability of IMKELDI, the first oral liquid...

Latigo Biotherapeutics ("Latigo") announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to LTG-001, the company's oral, investigational selective Nav1.8...